{"protocolSection": {"identificationModule": {"nctId": "NCT02336425", "orgStudyIdInfo": {"id": "CQGE031B2204"}, "secondaryIdInfos": [{"id": "2014-003155-57", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma", "officialTitle": "A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 Subcutaneous (s.c). in Asthma Patients Not Adequately Controlled by Medium- or High-dose Inhaled Corticosteroid (ICS) Plus Long Acting \u03b22-agonist (LABA) With or Without Oral Corticosteroid (OCS)"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "TERMINATED", "whyStopped": "This study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754).", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-09"}, "primaryCompletionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-01-08", "studyFirstSubmitQcDate": "2015-01-08", "studyFirstPostDateStruct": {"date": "2015-01-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-21", "resultsFirstSubmitQcDate": "2017-02-21", "resultsFirstPostDateStruct": {"date": "2017-04-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-08-07", "lastUpdatePostDateStruct": {"date": "2017-08-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist medication with or without oral steroid. However, this study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754). Planned data analyses were not performed for this study due to the early termination and the very limited dataset (only 10 participants received study medication of the 440 participants planned)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QGE031 240 mg", "type": "EXPERIMENTAL", "description": "QGE031 240 mg subcutaneous injection every 4 weeks", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 72 mg", "type": "EXPERIMENTAL", "description": "QGE031 72 mg subcutaneous injection every 4 weeks", "interventionNames": ["Drug: QGE031"]}, {"label": "QGE031 24 mg", "type": "EXPERIMENTAL", "description": "QGE031 24 mg subcutaneous injection every 4 weeks", "interventionNames": ["Drug: QGE031"]}, {"label": "Placebo to QGE031", "type": "PLACEBO_COMPARATOR", "description": "Placebo subcutaneous injection every 4 weeks", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "QGE031", "description": "QGE031 120 mg per 1 mL liquid in vial", "armGroupLabels": ["QGE031 24 mg", "QGE031 240 mg", "QGE031 72 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to QGE031 0 mg per 1 mL liquid in vial", "armGroupLabels": ["Placebo to QGE031"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "QGE031 Compared to Placebo in Atopic Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "timeFrame": "Week 52"}], "secondaryOutcomes": [{"measure": "QGE031 Compared to Placebo in All Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "timeFrame": "Week 52"}, {"measure": "QGE031 Compared to Placebo in Non-atopic Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "timeFrame": "Week 52"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on the Reduction in Rate of Asthma Exacerbations (by Severity)", "timeFrame": "Week 52"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Time to First Asthma Exacerbations (by Severity)", "timeFrame": "Week 52"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Change From Baseline in Asthma Control Questionnaire (ACQ)", "timeFrame": "Baseline, Treatment (Weeks 4, 8, 12, 16, 24, 36, 52), follow up (Weeks 60 and 72)"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Change From Baseline in Asthma Control Diary (ACD)", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Forced Expiratory Volume in 1 Second (FEV1)", "timeFrame": "Baseline, Treatment (Weeks 4, 8, 12, 16, 24, 36, 52), follow up (Weeks 60 and 72)"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Peak Expiratory Flow (PEF) in the Morning and Evening", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)"}, {"measure": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Total Daily Symptom Score", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)"}, {"measure": "Response to QGE031 Between Atopic Asthma and Non-atopic Asthma", "timeFrame": "Over 52 weeks (treatment) and 20 weeks (follow up)"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* A diagnosis of allergic asthma, uncontrolled on current medication.\n* History of at least 2 asthma exacerbations during the last 1 year\n* Forced Expiratory Volume in one second (FEV1) of \u2265 40% and \u2264 80% of the predicted normal value; reversibility following administration of bronchodilator.\n\nKey Exclusion Criteria:\n\n* Use of tobacco products within the previous 6 months (Social occasional smokers may be included).\n* Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novartis Investigative Site", "city": "Kingwood", "state": "Texas", "zip": "77339", "country": "United States", "geoPoint": {"lat": 30.03355, "lon": -95.26104}}, {"facility": "Novartis Investigative Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novartis Investigative Site", "city": "Erpent", "zip": "5100", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "Novartis Investigative Site", "city": "Toronto", "state": "Ontario", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novartis Investigative Site", "city": "Trois-Rivi\u00e8res", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Novartis Investigative Site", "city": "Le Kremlin Bicetre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Novartis Investigative Site", "city": "Cottbus", "state": "Sachsen", "zip": "03050", "country": "Germany", "geoPoint": {"lat": 51.75769, "lon": 14.32888}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12099", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Marburg", "zip": "35037", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Novartis Investigative Site", "city": "M\u00fcnster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "Novartis Investigative Site", "city": "Miskolc", "state": "HUN", "zip": "3529", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Novartis Investigative Site", "city": "Balassagyarmat", "zip": "2660", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Novartis Investigative Site", "city": "Pisa", "state": "PI", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Novartis Investigative Site", "city": "Sapporo-city", "state": "Hokkaido", "zip": "064-0804", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Novartis Investigative Site", "city": "Sakaide-city", "state": "Kagawa", "zip": "762-8550", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Sagamihara-city", "state": "Kanagawa", "zip": "228-8522", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "232-0024", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "234-8503", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Habikino-city", "state": "Osaka", "zip": "583-8588", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Novartis Investigative Site", "city": "Kishiwada-city", "state": "Osaka", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Novartis Investigative Site", "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Edogawa-ku", "state": "Tokyo", "zip": "134-0083", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Itabashi-ku", "state": "Tokyo", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Novartis Investigative Site", "city": "Ota-ku", "state": "Tokyo", "zip": "140-0063", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Novartis Investigative Site", "city": "Ota-ku", "state": "Tokyo", "zip": "143-0023", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Toshima-ku", "state": "Tokyo", "zip": "171-0014", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Harderwijk", "zip": "3840 AC", "country": "Netherlands", "geoPoint": {"lat": 52.34167, "lon": 5.62083}}, {"facility": "Novartis Investigative Site", "city": "Leiden", "zip": "2333 ZA", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.49306}}, {"facility": "Novartis Investigative Site", "city": "Bojnice", "state": "Slovak Republic", "zip": "972 01", "country": "Slovakia", "geoPoint": {"lat": 48.78511, "lon": 18.5864}}, {"facility": "Novartis Investigative Site", "city": "Liptovsky Hradok", "state": "Slovak Republic", "zip": "033 01", "country": "Slovakia", "geoPoint": {"lat": 49.03962, "lon": 19.72335}}, {"facility": "Novartis Investigative Site", "city": "Nitra", "state": "Slovak Republic", "zip": "949 01", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigative Site", "city": "Zvolen", "zip": "960 01", "country": "Slovakia", "geoPoint": {"lat": 48.57442, "lon": 19.15324}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were randomized to one of the four treatment arms.", "groups": [{"id": "FG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "FG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "FG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "FG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Study terminated.", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "BG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "BG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "BG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "10"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.5", "spread": "16.26"}, {"groupId": "BG001", "value": "47.0", "spread": "1.41"}, {"groupId": "BG002", "value": "53.7", "spread": "11.59"}, {"groupId": "BG003", "value": "47.7", "spread": "2.89"}, {"groupId": "BG004", "value": "49.1", "spread": "8.45"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "QGE031 Compared to Placebo in Atopic Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in All Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Non-atopic Asthma Patients on the Reduction in Rate of Severe Asthma Exacerbations", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on the Reduction in Rate of Asthma Exacerbations (by Severity)", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Time to First Asthma Exacerbations (by Severity)", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Change From Baseline in Asthma Control Questionnaire (ACQ)", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Treatment (Weeks 4, 8, 12, 16, 24, 36, 52), follow up (Weeks 60 and 72)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Change From Baseline in Asthma Control Diary (ACD)", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Forced Expiratory Volume in 1 Second (FEV1)", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Treatment (Weeks 4, 8, 12, 16, 24, 36, 52), follow up (Weeks 60 and 72)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Peak Expiratory Flow (PEF) in the Morning and Evening", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "QGE031 Compared to Placebo in Asthma Patients (All and Either Atopic or Non-atopic) on Total Daily Symptom Score", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Over 52 weeks (Treatment) and 20 weeks (follow-up)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Response to QGE031 Between Atopic Asthma and Non-atopic Asthma", "populationDescription": "Due to the small number of patients randomized and limited treatment duration (not more than 22 days in QGE031 and 29 days in Placebo), the planned statistical analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Over 52 weeks (treatment) and 20 weeks (follow up)", "groups": [{"id": "OG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks"}, {"id": "OG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks"}, {"id": "OG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks"}, {"id": "OG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "QGE031 240 mg", "description": "QGE031 240 mg subcutaneous injection every 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG001", "title": "QGE031 72 mg", "description": "QGE031 72 mg subcutaneous injection every 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}, {"id": "EG002", "title": "QGE031 24 mg", "description": "QGE031 24 mg subcutaneous injection every 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG003", "title": "Placebo to QGE031", "description": "Placebo subcutaneous injection every 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 2, "otherNumAtRisk": 3}], "otherEvents": [{"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 3}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Study was terminated due to the efficacy results from the Phase II study CQGE031B2201 (NCT01716754). Data analyses were not performed due to the very limited dataset (only 10 participants received study medication of the 440 participants planned)."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Russian Federation", "South Africa", "Spain"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}